Review articlePublished 3 Jul 2025
Efficacy of interventions for newly diagnosed multiple myeloma: An umbrella review
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Purpose: Many systematic reviews have examined treatment efficacy for newly diagnosed multiple myeloma (NDMM). We performed an umbrella review of these systematic reviews to provide a comprehensive examination of the current body of evidence, aiming to scope current review-level evidence and identify weaknesses in these reviews. Methods: We identified systematic reviews examining efficacy of NDMM interventions in multiple databases published from January 1, 1990 through July 10, 2023. We explored potentially concerning issues which may compromise the validity of the conclusions in these reviews. We assessed the reviews’ quality, summarized the findings, and present potential evidence gaps. Results: Eighty-seven reviews on NDMM treatment were included. Only seven assessed the strength of evidence. Treatments strategies like bortezomib-based induction for transplant-eligible patients, daratumumab for transplant-ineligible patients, and lenalidomide maintenance had moderate to high evidence. No reviews evaluated chimeric antigen receptor T-cell therapy or bispecific antibodies for NDMM. We identified five concerning issues: 1) inappropriate data abstraction (N=6), 2) inappropriate meta-analytic approaches (N=5), 3) not accounting for different induction strategies when evaluating the efficacy of consolidation/maintenance therapies (N=9), 4) implicit assumption that treatment efficacy is similar between transplant eligible and ineligible patients (N=13), and 5) inappropriate study selection (including observational studies or single-arm trials for treatment efficacy evaluation, which may lead to substantial biases; N=17). Conclusion: This umbrella review provided a contemporary analysis of treatment efficacy for NDMM. We identified several weaknesses in existing reviews, indicating additional scrutiny of publishing systematic reviews in MM is warranted.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Yimeng Li”
- BylineArticles whose byline prints “Mengmeng Ji”
- BylineArticles whose byline prints “Mark A. Fiala”
- BylineArticles whose byline prints “Enkhjin Gansukh”
- BylineArticles whose byline prints “Natalia Neparidze”
- BylineArticles whose byline prints “Martin W. Schoen”
- BylineArticles whose byline prints “Xiaomei Ma”
- BylineArticles whose byline prints “Graham A. Colditz”
